Aripiprazole Tablet
Product Images NDC 63629-7108

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 63629-7108). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (Image Fig1 Effectofotherdrug Arip)

A pharmacokinetic chart depicting the effects of various other drugs on aripiprazole. It shows aripiprazole fold change and 90% confidence intervals for AUC and Cmax values with drugs like ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam compared to reference (no interacting drug). The x-axis represents change relative to reference from 0.5 to 3.0.*

FDA Label Image

Image 2 (Image Fig2 Effectofotherdrug Dehydroarip)

A chart titled 'The effects of other drugs on dehydro-aripiprazole pharmacokinetics' showing fold changes and 90% confidence intervals for multiple drugs affecting aripiprazole levels. The x-axis represents change relative to reference without interacting drug, ranging from 0.5 to 3. Drugs include CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and others, with parameters AUC and Cmax measured for each.*

FDA Label Image

Image 3 (Image Fig3 Effectofarip Otherdrug)

A pharmacokinetic graph titled 'The effects of aripiprazole on pharmacokinetics of other drugs,' depicting fold changes and 90% confidence intervals for various drugs such as dextromethorphan, warfarin (S- and R- forms), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The x-axis represents change relative to reference without interacting drug, ranging from 0.5 to 3.0. The y-axis lists the drugs and pharmacokinetic parameters (e.g., AUC, Cmax, INR).*

FDA Label Image

Image 4 (Image Fig4 Effectofintrinsicfactor Arip)

A chart titled 'Effects of intrinsic factors on aripiprazole pharmacokinetics' showing fold change and 90% confidence intervals for aripiprazole exposure parameters (AUC and Cmax). It compares special populations including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment on the x-axis of change relative to reference.*

FDA Label Image

Image 5 (Image Fig5 Effectofintrinsicfactor Dehydroarip)

A pharmacokinetic chart showing the effects of intrinsic factors on dehydro-aripiprazole levels. The graph illustrates fold changes with 90% confidence intervals for variables including CYP2D6 metabolizer status, gender, age, hepatic impairment (mild, moderate, severe), and severe renal impairment, plotted against change relative to reference for AUC and Cmax values.*

FDA Label Image

Fig 6 (Image Fig6 Schizophreniastudy 5)

Kaplan-Meier curve showing cumulative proportion of patients with relapse over days from randomization in a schizophrenia study comparing aripiprazole and placebo. The graph includes lines for aripiprazole (blue) and placebo (red), with decreasing numbers of subjects at risk indicated below the x-axis.*

FDA Label Image

7 (Image Fig7 Bipolarstudy 7)

Kaplan-Meier plot showing the cumulative proportion of patients with relapse over 182 days from randomization in Bipolar Study 7, comparing aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The graph includes the number of subjects at risk at multiple time points for each group.*

FDA Label Image

8 (Image Fig8 Bipolarstudy 8)

Kaplan-Meier estimation chart showing the cumulative proportion of patients with relapse to any mood event over time (days from randomization) in a bipolar study. The graph compares ABILIFY (aripiprazole) versus placebo groups, with a table below indicating the number of subjects at risk at various time points.*

FDA Label Image

9 (Image Fig9 Tourettesdisorderstudy1)

A line graph titled 'Least Square Means of Change from Baseline in YGTSS TTS by Week (Tourette’s Disorder Study 1)' showing the change in YGTSS total tic score from baseline over 8 weeks of treatment. The graph includes three lines: ARIP-LOW, ARIP-HIGH, and PLACEBO, with ARIP-HIGH showing the greatest decrease in tic scores over time.*

FDA Label Image

Image (Image Logo Medguide)

FDA Label Image

Logo (Image Logo Pi)

FDA Label Image

Description Image (Image Structure)

Chemical structure diagram of aripiprazole showing the molecular arrangement of atoms and chemical bonds, including chlorinated aromatic rings and heterocyclic components.*

FDA Label Image

Label (Lbl636297108)

Label for aripiprazole 15 mg tablet packaged by Bryant Ranch Prepack. The label compares the product to Abilify 15 mg tablet by Torrent Pharmaceuticals Ltd. It notes the tablets are white to off-white, round, and includes storage instructions at 20-25°C (68-77°F). The NDC is 63629-7108, and the package contains 30 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.